FRNM +10% in pre-mkt ABT following earlier PR: Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Optio
FRNM +10% in pre-mkt ABT following earlier PR: Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment Link To Press Release
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.